NCT05323188 (KID-Tryp) is a clinical trial of Tryptase dosage in Basal Tryptasemia, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT05323188?

NCT05323188 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT05323188?

Interventions in NCT05323188: Tryptase dosage.

What condition does NCT05323188 study?

NCT05323188 studies Basal Tryptasemia.

Is NCT05323188 still recruiting?

NCT05323188 is currently completed. Last updated 12 September 2025.

Last reviewed 2025-09-12 · How we verify

NCT05323188: KID-Tryp

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Serum Basal Tryptase Levels in Healthy Children

Completed Last updated 12 September 2025

What this trial tests

trial testing Tryptase dosage in Basal Tryptasemia in 402 participants. Completed in 24 October 2022.

Timeline

21 April 2022

Primary endpoint
24 October 2022

24 October 2022

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Status	Completed
Study type	OBSERVATIONAL
Enrollment	402
Start date	21 April 2022
Primary completion	24 October 2022
Estimated completion	24 October 2022
Sites	1 location across France

Drugs / interventions tested

Tryptase dosage

Conditions studied

Basal Tryptasemia — all drugs for Basal Tryptasemia →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

Under 17, any sex, with Basal Tryptasemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The National REference Center for MASTocytosis (CEREMAST), located at the Necker-Enfants Malades Hospital, is particularly interested in two groups of rare diseases whose common point is excessive activation of mast cells: mastocytosis and mast cell activation syndromes (MCAS). Unlike MCAS, whose symptoms result solely from this aberrant mast cell activation, in mastocytosis there is, in addition, an expansion and a clonal accumulation of mast cells in different target organs. These two diseases are heterogeneous in their clinical presentation and can begin in early childhood. While the diagnostic criteria for mastocytosis are well established, those for MCAS are unclear, causing major diagnostic error and therefore poor patient care. To date, there is no study evaluating tryptase standards in children less than 18 years of age. The research focuses on the dosage of tryptase in a control population of children aged 0 to 18 years. Each patient receiving a complete blood count (CBC) in a surgery department of the Necker-Enfants Malades hospital will be selected to participate in the study. After the CBC analysis, the rest of the sample will be kept for this research instead of being discarded. Knowing the norms of tryptase according to age would be an important tool for dermatologists, allergists and pediatricians caring for patients suspected of MCAS or mastocytosis. A blood test could thus avoid a few years of diagnostic wandering in the MCAS and mastocytosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05323188 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 12 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05323188.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing